Hill-Rom acquires Aspen Surgical Products

Thursday, July 26, 2012 02:31 PM

Hill-Rom Holdings, a global healthcare technologies company, has completed the $400 million purchase of privately held Aspen Surgical Products, a Caledonia, Mich.-based provider of surgical consumable and specialty medical products.

Aspen’s product lines include Bard-Parker conventional and safety scalpels and blades, Colby fluid collection products, Richard-Allan specialty needles and a variety of other operating room disposables, instrument care products and wound care dressings. T

The acquisition of Aspen Surgical further develops Hill-Rom's surgical business, adding a portfolio of consumable products and expanding its position in North American and European surgical markets.

"With the addition of Aspen Surgical, Hill-Rom is well positioned for growth and geographic expansion in our surgical business, particularly in the safety product segments," said John J. Greisch, president and CEO of Hill-Rom.

Aspen Surgical has annual revenue of approximately $120 million. The transaction is expected to be accretive approximately $0.02 to fiscal year 2012 earnings per share, excluding non-recurring purchase accounting items and other acquisition and integration related costs.

"Aspen Surgical and Hill-Rom share a similar mission to enhance outcomes with products that help ensure a safe environment in surgical and other health care settings," added Greg Pritchard, formerly CEO of Aspen Surgical and now senior vice president and president, surgical and respiratory care, Hill-Rom. "We look forward to leveraging the valued Hill-Rom brand to expand Aspen Surgical's presence around the world."

Share:          
CWWeekly

July 6

FDA sued by advocacy groups seeking hepatitis C trials data

Google to test health-tracking wristband to collect clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs